| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3036741 | Brain and Development | 2016 | 7 Pages |
Abstract
Bromide is most effective and is a well-tolerated drug among DS patients, especially among SCN1A-negative patients. Carbamazepine should be avoided in patients with SCN1A mutations.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Xiu-Yu Shi, Yuko Tomonoh, Wen-Ze Wang, Atsushi Ishii, Norimichi Higurashi, Hirokazu Kurahashi, Sunao Kaneko, Shinichi Hirose, The Epilepsy Genetic Study Group, Japan (Chairperson, SK) The Epilepsy Genetic Study Group, Japan (Chairperson, SK),